Modification of severe insulin resistant diabetes in response to lifestyle changes in Alström syndrome

European Journal of Medical Genetics

Volumn 57, Issue 2-3, 2014, Pages 71-75

  Paisey, Richard B ^a   Geberhiwot, Tarekeng ^b   Waterson, Michael ^a   Cramb, Robert ^b   Steeds, Rick ^b   Williams, Kathleen ^a   White, Alison ^a   Hardy, Carol ^c  

^a TORBAY AND SOUTH DEVON NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alstr m syndrome; Exercise; Insulin resistance; Metabolic syndrome; Nutrition; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; BIOLOGICAL MARKER;

ADULT; AEROBIC EXERCISE; ALSTROM SYNDROME; ARTICLE; BLOOD GLUCOSE MONITORING; CARBOHYDRATE INTAKE; CASE REPORT; DIABETES CONTROL; DIABETES MELLITUS; EXERCISE; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER FUNCTION; MALE; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; WALKING; WEIGHT GAIN; WEIGHT REDUCTION; YOUNG ADULT; DIABETES MELLITUS, TYPE 2; GENETICS; KINESIOTHERAPY; LIFESTYLE; TREATMENT OUTCOME;

ADULT; ALSTROM SYNDROME; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; EXERCISE; EXERCISE THERAPY; FEMALE; HUMANS; INSULIN RESISTANCE; LIFE STYLE; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897108908     PISSN: 17697212     EISSN: 18780849     Source Type: Journal    
DOI: 10.1016/j.ejmg.2013.12.008     Document Type: Article

References (33)

1. Awazu M., Tanaka T., Sato S., Anzo M., Higuchi M., Yamazaki K., et al. Hepatic dysfunction in two sibs with Alström syndrome: case report and review of the literature. Am J Med Genet 1997, 69:13-16.
2. Badano J.L., Mitsuma N., Beales P.L., Katsanis N. The ciliopathies: an emerging class of human genetic disorders. Annu Rev Genomics Hum Genet 2006, 7:125-148.
3. Berger B., Stenström G., Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000, 60:687-693.
4. Bettini V., Maffei P., Pagano C., Romano S., Milan G., Favaretto F., et al. The progression from obesity to type 2 diabetes in Alström syndrome. Pediatr Diabetes 2012, 13:59-67.
5. Chang K.W., Hou J.W., Lin S.J., Kong M.S. Alstrom syndrome with hepatic dysfunction: report of one case. Acta Paediatr Taiwan 2000, 41:270-272.
6. Chou P.I., Chen C.H., Chen J.T., Wen L.Y., Wu D.A., Feldon S.E. Alström syndrome with subclinical insulin-resistant diabetes and hepatic dysfunction: a family report. JPediatr Ophthalmol Strabismus 2000, 37:179-182.
7. Collin G.B., Marshall J.D., King B.L., Milan G., Maffei P., Jagger D.J., et al. The Alström syndrome protein, ALMS1, interacts with α-actinin and components of the endosome recycling pathway. PloS One 2012, 7:e37925.
8. Connolly M.B., Jan J.E., Couch R.M., Wong L.T., Dimmick J.E., Rigg J.M. Hepatic dysfunction in Alström disease. Am J Med Genet 1991, 40:421-424.
9. Daly M.E., Paisey R., Paisey R., Millward B.A., Eccles C., Williams K., et al. Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes-a randomized controlled trial. Diabet Med J Br Diabet Assoc 2006, 23:15-20.
10. Diabetes Prevention Program Research 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
11. Hayashi T., Wojtaszewski J.F.P., Goodyear L.J. Exercise regulation of glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab 1997, 273:E1039-E1051.
12. Hearn T., Spalluto C., Phillips V.J., Renforth G.L., Copin N., Hanley N.A., et al. Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Diabetes 2005, 54:1581-1587.
13. Jagger D., Collin G., Kelly J., Towers E., Nevill G., Longo-Guess C., et al. Alström syndrome protein ALMS1 localizes to basal bodies of cochlear hair cells and regulates cilium-dependent planar cell polarity. Hum Mol Genet 2011, 20:466-481.
14. Jatti K., Paisey R., More R. Coronary artery disease in Alström syndrome. Eur J Hum Genet 2012, 20:117-118.
15. Johnston D.G., Alberti K.G., Binder C., Faber O.K., Wright R., Orskov H. Hormonal and metabolic changes in hepatic cirrhosis. Horm Metab Res 1982, 14:34-39.
16. Jones A.G., Hattersley A.T. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med J Br Diabet Assoc 2013, 30:803-817.
17. Ciliopathies: a reference for clinicians 2013, Oxford University Press, New York, NY. 1st edition. T.D. Kenny, P.L. Beales (Eds.).
18. Lee N.-C., Marshall J.D., Collin G.B., Naggert J.K., Chien Y.-H., Tsai W.-Y., et al. Caloric restriction in Alström syndrome prevents hyperinsulinemia. Am J Med Genet A 2009, 149A:666-668.
19. Lindström J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemiö K., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
20. Loudon M.A., Bellenger N.G., Carey C.M., Paisey R.B. Cardiac magnetic resonance imaging in Alström syndrome. Orphanet J Rare Dis 2009, 4:14.
21. Marshall J.D., Bronson R.T., Collin G.B., Nordstrom A.D., Maffei P., Paisey R.B., et al. New Alström syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med 2005, 165:675-683.
22. Marshall J.D., Beck S., Maffei P., Naggert J.K. Alström syndrome. Eur J Hum Genet 2007, 15:1193-1202.
23. Mokashi A., Cummings E.A. Presentation and course of diabetes in children and adolescents with Alstrom syndrome. Pediatr Diabetes 2011, 12:270-275.
24. Paisey R.B., Carey C.M., Bower L., Marshall J., Taylor P., Maffei P., et al. Hypertriglyceridaemia in Alström's syndrome: causes and associations in 37 cases. Clin Endocrinol (Oxf) 2004, 60:228-231.
25. Paisey R.B., Hodge D., Williams K. Body fat distribution, serum glucose, lipid and insulin response to meals in Alström syndrome. JHum Nutr Diet 2008, 21:268-274.
26. Paisey R.B. New insights and therapies for the metabolic consequences of Alström syndrome. Curr Opin Lipidol 2009, 20:315-320.
27. Parkes J., Roderick P., Harris S., Day C., Mutimer D., Collier J., et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010, 59:1245-1251.
28. Perry E., Gallen I. Guidelines on the current best practice for the management of type 1 diabetes, sport and exercise. Pract Diabetes Int 2009, 26:116-123.
29. Romano S., Milan G., Veronese C., Collin G.B., Marshall J.D., Centobene C., et al. Regulation of Alström syndrome gene expression during adipogenesis and its relationship with fat cell insulin sensitivity. Int J Mol Med 2008, 21:731-736.
30. Saisho Y., Kou K., Tanaka K., Abe T., Kurosawa H., Shimada A., et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 2011, 58:315-322.
31. Waters A.M., Beales P.L. Ciliopathies: an expanding disease spectrum. Pediatr Nephrol Berl Ger 2011, 26:1039-1056.
32. Wing R.R., Bolin P., Brancati F.L., Bray G.A., Clark J.M., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. NEngl J Med 2013, 369:145-154. Look AHEAD Research Group.
33. Zulato E., Favaretto F., Veronese C., Campanaro S., Marshall J.D., Romano S., et al. ALMS1-deficient fibroblasts over-express extra-cellular matrix components, display cell cycle delay and are resistant to apoptosis. PloS One 2011, 6:e19081.